AllPennyStocks.com MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID

The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.

Other Penny Stock Movers

When Design Thinking Meets the AI Canvas
Brazilian Developer Jumps 11% as Court Lifts Injunction
Deep Utah Porphyry Intercept Triggers 57% Rally as Drilling Continues Past 550m
Most Popular
{{ index + 1 }}


Back to Top